The India irritable bowel syndrome treatment market is expected to register a CAGR of 11.64%, over the forecast years. The country’s market growth is mainly attributed to key drivers, such as, the increased incidence of irritable bowel syndrome, the lack of proper sanitation, and the depletion of potable drinking water. The base year considered for the market study is 2020, and the forecast period is from 2021 to 2026.
INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2026
India Irritable Bowel Syndrome Treatment Market by Type (Ibs With Diarrhea, Ibs With Constipation, Mixed Ibs) by Product (Rifaximin, Eluxadoline, Linaclotide, Lubiprostone, Other Products) by Distribution Channel (Drug Stores and Retail Pharmacies, Hospitals’ Pharmacies, Online Pharmacies) by Mechanism of Action (5ht3 Antagonist, Guanylate Cyclase Receptor-c Agonist, Chloride Channel Activator, Other Mechanism of Actions) by Dosage (Solid, Liquid)
The India irritable bowel syndrome treatment market is expected to register a CAGR of 11.64%, over the forecast years. The country’s market growth is mainly attributed to key drivers, such as, the increased incidence of irritable bowel syndrome, the lack of proper sanitation, and the depletion of potable drinking water. The base year considered for the market study is 2020, and the forecast period is from 2021 to 2026.
To learn more about this report, request a free sample copy
According to studies, the prevalence of irritable bowel syndrome (IBS) in India varies from 10% to 20%. While sex, marital and socioeconomic status, and religion were not linked to irritable bowel syndrome, factors like sexual function, psychiatric disorders, pelvic pain, work absenteeism, and gastroesophageal reflux diseases were significantly associated with the condition.
The depletion of potable drinking water, in addition to the lack of proper sanitation, results in digestive systems’ disorders. Moreover, they lead to the majority of digestive and water-borne diseases, as well. India’s increasing geriatric population base is further expected to fuel the country’s market growth. As reported by the United Nations Population Fund, the number of elderly individuals is anticipated to increase to nearly 173 million, by 2026. Hence, these factors are set to supplement the India irritable bowel syndrome treatment market growth over the forecast period.
AstraZeneca PLC, headquartered in the United Kingdom, is an international innovation-driven biopharmaceutical company. It specializes in the development, manufacture, and marketing of prescription medicine. The company also discovers new and innovative drugs, designed to enhance the health as well as the quality of life of patients, worldwide.
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- COUNTRY SNAPSHOT
- COUNTRY ANALYSIS
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY ANALYTICS
- PORTER’S FIVE FORCES ANALYSIS
- THREAT OF NEW ENTRY
- THREAT OF SUBSTITUTION
- BUYER’S POWER
- SUPPLIER’S POWER
- COMPETITIVE RIVALRY
- IMPACT OF COVID-19 ON IRRITABLE BOWEL SYNDROME TREATMENT MARKET
- REGULATORY FRAMEWORK
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- KEY INVESTMENT INSIGHTS
- PORTER’S FIVE FORCES ANALYSIS
- MARKET BY TYPE
- IBS WITH DIARRHEA
- IBS WITH CONSTIPATION
- MIXED IBS
- MARKET BY PRODUCT
- RIFAXIMIN
- ELUXADOLINE
- LINACLOTIDE
- LUBIPROSTONE
- OTHER PRODUCTS
- MARKET BY DISTRIBUTION CHANNEL
- DRUG STORES AND RETAIL PHARMACIES
- HOSPITALS’ PHARMACIES
- ONLINE PHARMACIES
- MARKET BY MECHANISM OF ACTION
- 5HT3 ANTAGONIST
- GUANYLATE CYCLASE RECEPTOR-C AGONIST
- CHLORIDE CHANNEL ACTIVATOR
- OTHER MECHANISM OF ACTIONS
- MARKET BY DOSAGE
- SOLID
- LIQUID
- COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
- MERGER & ACQUISITIONS
- PRODUCT LAUNCH & DEVELOPMENTS
- PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
- BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
- COMPANY PROFILE
- ABBOTT LABORATORIES
- ALLERGAN PLC
- ASTRAZENECA PLC
- GLAXOSMITHKLINE PLC
- NOVARTIS AG
- KEY STRATEGIC DEVELOPMENTS
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – IRRITABLE BOWEL SYNDROME TREATMENT
TABLE 2: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 3: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2021-2026 (IN $ MILLION)
TABLE 4: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 5: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, FORECAST YEARS, 2021-2026 (IN $ MILLION)
TABLE 6: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 7: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2021-2026 (IN $ MILLION)
TABLE 8: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 9: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, FORECAST YEARS, 2021-2026 (IN $ MILLION)
TABLE 10: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 11: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, FORECAST YEARS, 2021-2026 (IN $ MILLION)
LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: OPPORTUNITY MATRIX
FIGURE 3: VENDOR LANDSCAPE
FIGURE 4: KEY INVESTMENT INSIGHTS
FIGURE 5: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, IN 2020
FIGURE 6: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH DIARRHEA, 2021-2026 (IN $ MILLION)
FIGURE 7: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH CONSTIPATION, 2021-2026 (IN $ MILLION)
FIGURE 8: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MIXED IBS, 2021-2026 (IN $ MILLION)
FIGURE 9: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, IN 2020
FIGURE 10: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY RIFAXIMIN, 2021-2026 (IN $ MILLION)
FIGURE 11: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ELUXADOLINE, 2021-2026 (IN $ MILLION)
FIGURE 12: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LINACLOTIDE, 2021-2026 (IN $ MILLION)
FIGURE 13: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LUBIPROSTONE, 2021-2026 (IN $ MILLION)
FIGURE 14: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER PRODUCTS, 2021-2026 (IN $ MILLION)
FIGURE 15: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, IN 2020
FIGURE 16: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DRUG STORES AND RETAIL PHARMACIES, 2021-2026 (IN $ MILLION)
FIGURE 17: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY HOSPITALS’ PHARMACIES, 2021-2026 (IN $ MILLION)
FIGURE 18: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ONLINE PHARMACIES, 2021-2026 (IN $ MILLION)
FIGURE 19: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, IN 2020
FIGURE 20: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY 5HT3 ANTAGONIST, 2021-2026 (IN $ MILLION)
FIGURE 21: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY GUANYLATE CYCLASE RECEPTOR-C AGONIST, 2021-2026 (IN $ MILLION)
FIGURE 22: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY CHLORIDE CHANNEL ACTIVATOR, 2021-2026 (IN $ MILLION)
FIGURE 23: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER MECHANISM OF ACTIONS, 2021-2026 (IN $ MILLION)
FIGURE 24: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, IN 2020
FIGURE 25: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY SOLID, 2021-2026 (IN $ MILLION)
FIGURE 26: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LIQUID, 2021-2026 (IN $ MILLION)
- MARKET BY TYPE
- IBS WITH DIARRHEA
- IBS WITH CONSTIPATION
- MIXED IBS
- MARKET BY PRODUCT
- RIFAXIMIN
- ELUXADOLINE
- LINACLOTIDE
- LUBIPROSTONE
- OTHER PRODUCTS
- MARKET BY DISTRIBUTION CHANNEL
- DRUG STORES AND RETAIL PHARMACIES
- HOSPITALS’ PHARMACIES
- ONLINE PHARMACIES
- MARKET BY MECHANISM OF ACTION
- 5HT3 ANTAGONIST
- GUANYLATE CYCLASE RECEPTOR-C AGONIST
- CHLORIDE CHANNEL ACTIVATOR
- OTHER MECHANISM OF ACTIONS
- MARKET BY DOSAGE
- SOLID
- LIQUID
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.